Molecular Therapy

FIGURE 1

FROM:

A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen–Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer

Eric J. Small, Michael A. Carducci, James M. Burke, Ron Rodriguez, Lawrence Fong, Lynn van Ummersen, D. C. Yu, Junko Aimi, Dale Ando, Peter Working, David Kirn and George Wilding

BACK TO ARTICLE

Figure 1.

Figure and tables index
Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Representative laboratory data on the two patients treated with the highest dose of CG7870 (6 times 1012 vp). (A) D-dimer; (B) prothrombin time (PT), partial thromboplastin time (PTT); (C) aspartate transaminase, alanine transaminase; (D) platelets; (E) lymphocytes.

Figure and tables index
BACK TO ARTICLE